ArticleJournal of blood medicine2022

Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States.

Yanyu Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.